SAR — Sareum Holdings Share Price
Last trade - 00:00- £24.12m
- £23.72m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 57.85 | ||
| Price to Tang. Book | 57.85 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -328.15% | ||
| Return on Equity | -257.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | 0.05 | n/a | n/a | n/a | 57 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
Directors
- Stephen Parker NEC (63)
- Tim Mitchell CEO (61)
- John Reader FDR (54)
- Tony Bunn SEC
- Clive Birch NED (68)
- Michael Owen NED (70)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 7th, 2004
- Public Since
- October 11th, 2004
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 101,578,309
- Address
- Unit 2A, CAMBRIDGE, CB22 3FX
- Web
- https://sareum.com/
- Phone
- +44 1223497700
- Auditors
- Shipleys LLP
Latest News for SAR
Upcoming Events for SAR
Full Year 2024 Sareum Holdings PLC Earnings Release
Similar to SAR
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:19 UTC, shares in Sareum Holdings are trading at 23.75p. This share price information is delayed by 15 minutes.
Shares in Sareum Holdings last closed at 23.75p and the price had moved by -76.83% over the past 365 days. In terms of relative price strength the Sareum Holdings share price has underperformed the FTSE All Share Index by -76.82% over the past year.
The overall consensus recommendation for Sareum Holdings is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sareum Holdings does not currently pay a dividend.
Sareum Holdings does not currently pay a dividend.
Sareum Holdings does not currently pay a dividend.
To buy shares in Sareum Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 23.75p, shares in Sareum Holdings had a market capitalisation of £24.12m.
Here are the trading details for Sareum Holdings:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SAR
Based on an overall assessment of its quality, value and momentum Sareum Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sareum Holdings is 176.00p. That is 641.05% above the last closing price of 23.75p.
Analysts covering Sareum Holdings currently have a consensus Earnings Per Share (EPS) forecast of -£0.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sareum Holdings. Over the past six months, its share price has underperformed the FTSE All Share Index by -67.42%.
As of the last closing price of 23.75p, shares in Sareum Holdings were trading -61.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sareum Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 23.75p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sareum Holdings' management team is headed by:
- Stephen Parker - NEC
- Tim Mitchell - CEO
- John Reader - FDR
- Tony Bunn - SEC
- Clive Birch - NED
- Michael Owen - NED